Document:

Fifth Amended and Restated Voting Agreement

 Exhibit 4.9 
 CODEXIS, INC. 
 FIFTH AMENDED AND RESTATED VOTING
AGREEMENT 
 This Fifth Amended and Restated Voting Agreement (the “Agreement”) is made and entered
into as of March 4, 2009, by and among Codexis, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Exhibit A hereto (the “Investors”). 
 RECITALS 
 WHEREAS, certain of the Investors hold shares of common stock of the Company (“Common Stock”), Series A Preferred Stock of the Company (“Series A Preferred Stock”), Series B Preferred Stock of the Company
(“Series B Preferred Stock”), Series C Preferred Stock of the Company (“Series C Preferred Stock”), Series D Preferred Stock of the Company (“Series D Preferred Stock”) and/or Series E Preferred
Stock of the Company (“Series E Preferred Stock”) and, together with the Company, are parties to that certain Fourth Amended and Restated Voting Agreement dated November 13, 2007 (the “Prior Agreement”);

 WHEREAS, certain Investors are purchasing shares of the Company’s Series F Preferred Stock (“Series F
Preferred Stock”, and together with the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock, the “Preferred Stock”),
pursuant to a Series F Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith (the “Financing”); 
 WHEREAS, the parties to the Prior Agreement desire to terminate the Prior Agreement and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; 

WHEREAS, in connection with the Financing, the Company’s Board of Directors (the “Board”) is increasing the number
of authorized members of the Board to ten (10); 
 WHEREAS, the obligations in the Purchase Agreement are conditioned upon the
execution and delivery of this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements contained in this Agreement and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree that the Prior Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as
follows: 
 1. Voting. 
 1.1 Investor Shares. The Investors each agree to hold all shares of voting capital stock of the Company (including but not limited to all shares of Common Stock issued upon conversion of the Preferred Stock) registered in their
respective names or beneficially owned by them as of the date hereof and any and all other securities of the Company legally or beneficially acquired by each of the Investors after the date hereof (collectively, the “Investor Shares”)
subject to, and to vote the Investor Shares in accordance with, the provisions of this Agreement. 

 1.2 Board of Directors. The holders of Investor Shares shall vote at a regular or
special meeting of stockholders (or by written consent) such shares that they own (or as to which they have voting power) to ensure that the size of the Board shall be set and remain at ten (10) directors; provided, however, that, subject to
the Company’s Seventh Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, such Board size may be subsequently increased or decreased pursuant to an amendment of this Agreement in accordance with
Section 3.5 hereof and, in addition, as may be increased pursuant to Section D.5(a)(iv), D.5(b)(iv), D.5(c)(iv), and/or D.5(d) of Article IV of the Company’s Seventh Amended and Restated Certificate of Incorporation. 
 1.3 Election of Directors. On all matters relating to the election of directors of the Company, the Investors agree to vote all
Investor Shares held by them (or the holders thereof shall consent pursuant to an action by written consent of the holders of capital stock of the Company) so as to elect (whether through a class vote, cumulative voting or otherwise) members of the
Board, as follows: 
 (a) one (1) nominee of the Series F Preferred Stock designated by Equilon Enterprises LLC dba Shell
Oil Products US (the “Shell Series F Representative”), so long as (i) Equilon Enterprises LLC dba Shell Oil Products US and its affiliates (“Shell”) holds on the date of such designation not less than fifty
percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series F Preferred Stock originally purchased by Shell (as adjusted for conversions, stock splits, dividends and the like), (ii) Shell
holds on the date of such designation not less than seven percent (7%) of the Fully Diluted Capitalization (as defined below), and (iii) that certain Amended and Restated Collaborative Research Agreement, entered into as of
November 1, 2007 and effective as of November 1, 2006, as amended, between Shell and the Company, has not expired or been terminated (other than a termination by Shell arising out of or resulting from a breach of such agreement by the
Company) prior to or on the date of such designation; provided, however, that, after the IPO, Shell’s designation of a nominee shall be subject to the reasonable approval of a majority of the members of the Board or the applicable committee of
the Board other than the Shell Representatives (as defined below). 
 (b) one (1) nominee of the Series E Preferred Stock
designated by Shell (the “Shell Series E Representative”), so long as (i) Shell holds on the date of such designation not less than fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon
conversion of the Series E Preferred Stock originally purchased by Shell (as adjusted for conversions, stock splits, dividends and the like), (ii) Shell holds on the date of such designation not less than five percent (5%) of the Fully
Diluted Capitalization (as defined below), and (iii) that certain Amended and Restated Collaborative Research Agreement, entered into as of November 1, 2007 and effective as of November 1, 2006, as amended, between Shell and the
Company, has not expired or been terminated (other than a termination by Shell arising out of or resulting from a breach of such agreement by the Company) prior to or on the date of such designation, which designee shall initially be William
Rothwell, Ph.D.; provided, however, that, after the IPO, Shell’s designation of a nominee shall be subject to the reasonable approval of a majority of the members of the Board or the applicable committee of the Board other than the Shell
Representatives. For purposes of this Agreement, the Shell Series E Representative and the Shell Series F Representative shall collectively be referred to herein as the “Shell Representatives.” 
  

 2 

 (c) one (1) nominee of the Series D Preferred Stock designated by Biomedical Sciences
Investment Fund Pte Ltd (the “Bio*One Representative”), so long as Biomedical Sciences Investment Fund Pte Ltd and its affiliates (“Bio*One”) hold not less than fifty percent (50%) of the total number of shares
of Common Stock issuable or issued upon conversion of the Series D Preferred Stock originally purchased by Bio*One (as adjusted for conversions, stock splits, dividends and the like) on the date of such designation; 
 (d) two (2) nominees of the Series B Preferred Stock designated as follows: 
 (i) one nominee designated by CMEA Ventures Life Sciences 2000, L.P. (the “CMEA Representative”), so long as CMEA Ventures
Life Sciences 2000, L.P. and its affiliates (“CMEA”) hold not less than fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series B Preferred Stock originally purchased
by CMEA (as adjusted for conversions, stock splits, dividends and the like) on the date of such designation, which designee shall initially be Thomas Baruch; and 
 (ii) one nominee designated by FirstMark III, L.P. and its affiliates (the “FirstMark Representative”), so long as FirstMark III, L.P. and its affiliates (“FirstMark”)
hold not less than fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series B Preferred Stock originally purchased by FirstMark (as adjusted for conversions, stock splits, dividends and
the like) on the date of such designation. 
 (e) one (1) nominee of the Series A Preferred Stock designated by Maxygen,
Inc., a Delaware corporation (“Maxygen”), so long as Maxygen and its affiliates hold not less than fifty percent (50%) of the total number shares of Common Stock issuable or issued upon conversion of the Series A Preferred
Stock originally purchased by Maxygen (as adjusted for conversions, stock splits, dividends and the like) on the date of such designation, which designee shall initially be Russell Howard; 
 (f) the person serving as Chief Executive Officer of the Company, or if there is no duly elected Chief Executive Officer, a nominee chosen
from Company management by the parties hereto holding a majority of the outstanding Common Stock and Preferred Stock, voting together as a single class on an as converted to Common Stock basis; and 
 (g) three (3) independent nominees, designated with the consent of the parties hereto holding a majority of the outstanding Common
Stock and Preferred Stock, voting together as a single class on an as-converted to Common Stock basis, which designees shall initially be Bernard Kelley, Bruce Pasternack, and Dennis Wolf. 
 Any vote taken to remove any director elected pursuant to this Section 1.3, or to fill any vacancy created by the resignation, removal
or death of a director elected pursuant to this Section 1.3, shall also be subject to the provisions of this Section 1.3 (i.e., removal shall be upon the written recommendation of the party/group that nominated such director and any
vacancy shall be filled upon the written recommendation of the party/group that nominated the director previously filling the position); provided, however, that, after the IPO, Shell’s designation of a nominee shall be subject to the reasonable
approval of a majority of the members of the Board or the applicable committee of the Board other than the Shell Representatives. 
  

 3 

 If the Company adopts a classified board structure, subject to the fiduciary duties of the
Board under applicable law, Shell shall have the right to determine the class in which the Shell Representatives shall serve at the time of such initial designation by the Board. 
 “Fully Diluted Capitalization,” at any particular time, means the sum of: (a) the total number of shares of Common
Stock that are issued and outstanding at such time; (b) the total number of shares of Common Stock that are issuable upon the conversion in full of all shares of Preferred Stock issued and outstanding at such time; (c) the total number of
shares of Common Stock that are issuable upon the conversion or exercise in full of all convertible securities, options, warrants or other rights to acquire Common Stock or Preferred Stock that are outstanding at such time (whether vested or
unvested); and (d) the total number of shares of Common Stock that are available for grant or issuance (but not outstanding) under the Company’s option and other benefit plans. 
 1.4 Board Committee Representation/Chairman. Each of the Shell Representatives, the CMEA Representative, the FirstMark Representative
and the Bio*One Representative shall have the right, but not the obligation, to be a member of any committee of the Board. 
 1.5 No Liability for Election of Recommended Director. None of the parties hereto and no officer, director, stockholder, partner, employee or agent of any party makes any representation or warranty as to the fitness or competence of
the nominee of any party hereunder to serve on the Board by virtue of such party’s execution of this Agreement or by the act of such party in voting for such nominee pursuant to this Agreement. 
 1.6 Legend. 
 (a) Concurrently with the execution of this Agreement, there shall be imprinted or otherwise placed, on certificates representing the Investor Shares the following restrictive legend (the “Legend”): 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A VOTING AGREEMENT THAT PLACES
CERTAIN RESTRICTIONS ON THE VOTING OF THE SHARES REPRESENTED HEREBY. ANY PERSON ACCEPTING ANY INTEREST IN SUCH SHARES SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SUCH AGREEMENT. A COPY OF SUCH VOTING AGREEMENT WILL BE
FURNISHED TO THE RECORD HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF BUSINESS.” 
  

 4 

 (b) The Company agrees that, during the term of this Agreement, it will not remove, and will
not permit to be removed (upon registration of reissuance or otherwise, except upon registration of transfer for consideration after the IPO), the Legend from any such certificate and will place or cause to be placed the Legend on any new
certificate issued to represent Investor Shares theretofore represented by a certificate carrying the Legend. 
 1.7
Successors. The provisions of this Agreement shall be binding upon the successors in interest to any of the Investor Shares other than transferees for consideration after the IPO. Prior to the IPO, the Company shall not permit the transfer of
any of the Investor Shares on its books or issue a new certificate representing any of the Investor Shares unless and until the person to whom such security is to be transferred shall have executed an additional counterpart signature page of this
Agreement whereby such person shall become a party to this Agreement and shall be bound by all the provisions hereof as if such person were an Investor, as applicable. No party to this Agreement may assign or otherwise transfer any of its rights or
obligations under this Agreement apart from the shares of capital stock owned by such party. 
 1.8 Other Rights. Except
as provided by this Agreement or any other agreement entered into in connection with the Financing, each Investor shall exercise the full rights of a holder of capital stock of the Company with respect to the Investor Shares, respectively.

 1.9 Covenants of the Company. The Company agrees to take all reasonable actions required to ensure that the rights
given to the parties hereunder are effective and that they enjoy the benefits thereof. The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be performed hereunder by the Company,
but will at all times in good faith assist in the carrying out of all of the provisions of this Agreement and in the taking of all such reasonable actions as may be necessary or appropriate in order to protect the rights of the parties hereunder
against impairment. 
 2. Termination. 
 2.1 General Termination. Subject to Section 2.2 with respect to Shell only, this Agreement shall continue in full force and effect from the date hereof through the earliest of the following
times, at which time the provisions of this Agreement, other than Sections 1.3(a), 1.3(b), 2.2 and 3 (except for Sections 3.1, 3.2 and 3.9) hereof (collectively, the “Shell Provisions”), shall terminate in their entirety:

 (a) immediately prior to the closing of a firmly underwritten public offering of the Common Stock pursuant to a registration
statement filed with the Securities and Exchange Commission, and declared effective under the Securities Act of 1933, as amended, which results in the Preferred Stock being converted into Common Stock (the “IPO”); 
 (b) ten (10) years from the date of this Agreement; 
 (c) immediately prior to the closing of a sale, lease, or other disposition of all or substantially all of the Company’s assets or the Company’s merger into or consolidation with any other
corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than
fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction; provided, however, that this Section 2.1(c) shall not apply to a merger effected exclusively for the purpose of changing
the domicile of the Company (a “Change in Control”); or 
  

 5 

 (d) the date as of which the parties hereto terminate this Agreement by written consent of:

 (i) Maxygen (provided at the time of termination Maxygen and its affiliates own at least fifty percent (50%) of the
total number shares of Series A Preferred Stock outstanding as of the date hereof (as adjusted for conversions, stock splits, dividends and the like)), 
 (ii) CMEA (provided at the time of termination CMEA owns at least fifty percent (50%) of the total number of shares of Series B Preferred Stock held as of the date hereof (as adjusted for
conversions, stock splits, dividends and the like)), 
 (iii) FirstMark (provided at the time of termination FirstMark owns at
least fifty percent (50%) of the total number of shares of Series B Preferred Stock held as of the date hereof (as adjusted for conversions, stock splits, dividends and the like)), 
 (iv) Bio*One (provided at the time of termination Bio*One owns at least fifty percent (50%) of the total number of shares of Series D
Preferred Stock held as of the date hereof (as adjusted for conversions, stock splits, dividends and the like)), 
 (v) Shell
(provided that, on the date of such written consent, Shell retains the right to elect at least one (1) Shell Representative to the Board pursuant to Sections 1.3(a) and/or 1.3(b) hereof) and 
 (vi) a majority in interest of, collectively, the Investors. 
 2.2 Shell Termination. For the benefit of Shell only, the Shell Provisions of this Agreement shall continue in full force and effect from the date hereof through the earliest of the following
dates, on which date the Shell Provisions (except for the last sentence of this Section 2.2, which shall terminate after the resignation of the Shell Representatives) shall terminate in their entirety: 
 (a) ten (10) years from the date of this Agreement; 
 (b) immediately prior to the closing of a Change in Control; 
 (c) the date as of
which the parties hereto terminate this Agreement with the written consent of Shell (provided at the time of termination Shell owns at least fifty percent (50%) of the total number of shares of Common Stock issued or issuable upon conversion of
the Series E Preferred Stock and the Series F Preferred Stock (voting together as a single class and not as a separate series and on an as-if-converted basis) originally purchased by Shell (as adjusted for conversions, stock splits, dividends and
the like)); 
 (d) the date as of which Shell holds less than five percent (5%) of the Fully Diluted Capitalization; or

  

 6 

 (e) the date as of which that certain Amended and Restated Collaborative Research Agreement,
entered into as of November 1, 2007 and effective as of November 1, 2006, as amended, has expired or been terminated other than a termination by Shell arising out of or resulting from a breach of such agreement by the Company (each of
such times in Sections 2.2(a) through 2.2(e) hereof being a “Shell Termination Trigger”). 
 Upon a Shell
Termination Trigger, Shell shall cause the Shell Representatives to resign from the Board and any committees of the Board on which such Shell Representatives sit, upon the request of a majority of the members of the Board or the applicable
committees of the Board other than the Shell Representatives. 
 3. Miscellaneous. 
 3.1 Ownership. Each Investor represents and warrants to the other Investors and the Company that (a) such Investor now owns the
Investor Shares, free and clear of liens or encumbrances, and has not, prior to or on the date of this Agreement, executed or delivered any proxy or entered into any other voting agreement or similar arrangement other than one that has expired or
terminated prior to or on the date hereof, and (b) such Investor has full power and capacity to execute, deliver and perform this Agreement, which has been duly executed and delivered by, and evidences the valid and binding obligation of, such
Investor enforceable in accordance with its terms. 
 3.2 Further Action. If and whenever the Investor Shares are sold
prior to the IPO, each Investor shall do all things and execute and deliver all documents and make all transfers, and cause any transferee of the Investor Shares to do all things and execute and deliver all documents, as may be necessary in good
faith to consummate such sale consistent with this Agreement. 
 3.3 Specific Performance. The parties hereto hereby
declare that it is impossible to measure in money the damages that will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement, that such a
breach would cause irreparable harm to the parties and agree that the terms of this Agreement shall be specifically enforceable by equitable remedies, including, but not limited to, temporary, preliminary and injunctive relief, specific performance
and the right to compel the breaching party to vote his or its capital stock of the Company in accordance with the provisions of the Agreement. If any party hereto or his heirs, personal representatives, or assigns institutes any action or
proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such
person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 
 3.4 Governing
Law. This Agreement, and the rights of the parties hereto, shall be governed by and construed in accordance with the laws of the State of Delaware as such laws apply to agreements among Delaware residents made and to be performed entirely within
the State of Delaware. 
  

 7 

 3.5 Amendment or Waiver. This Agreement may be amended (or provisions of this
Agreement waived) only by an instrument in writing signed by (i) the Company and (ii) the holders of at least a majority of the Preferred Stock, voting together as a single class on an as-converted basis and including any Common Stock
issued upon conversion, except as provided below. 
 Any amendment or waiver so effected shall be binding upon the Company, each
of the parties hereto and any assignee of any such party; provided, however, that notwithstanding the foregoing, the consent of any Investor having the right to designate or remove a director pursuant to Section 1.3 of this Agreement
and/or a committee appointment right pursuant to Section 1.4, as applicable, shall be required for any amendment, supplement, modification or waiver of such rights (provided at the time of such amendment, supplement, modification or waiver,
such Investor owns at least fifty percent (50%) of the total number of shares of Common Stock issued or issuable upon conversion of the shares of the relevant series of Preferred Stock purchased by such Investor (for instance, with respect to
Shell, the Series E Preferred Stock or Series F Preferred Stock, as applicable), which shares are held by such Investor as of the date hereof (as adjusted for conversions, stock splits, dividends and the like)); provided, further, however, that no
amendment or waiver of this Agreement shall materially and adversely affect the rights of an Investor in a manner that materially and disproportionately discriminates against such Investor in relation to the other Investors without such
Investor’s written consent; provided, further, however, that the addition of new parties to this Agreement or the proportionate adjustment in rights that would result from adding new parties (including in connection with the addition of new
seats to the Board) shall not be deemed to be an amendment or waiver which materially and disproportionately discriminate against such Investor. 
 3.6 Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 
 3.7 Successors. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs,
successors, assigns, administrators, executors and other legal representatives. 
 3.8 Additional Shares. In the event
that subsequent to the date of this Agreement any shares or other securities are issued on, or in exchange for, any of the Investor Shares by reason of any stock dividend, stock split, combination of shares, reclassification or the like, such shares
or securities shall be deemed to be Investor Shares for purposes of this Agreement. 
 3.9 Addition of Investors.
Notwithstanding anything to the contrary contained herein, if, prior to the IPO, the Company (i) shall issue additional shares of its Preferred Stock pursuant to the Purchase Agreement or (ii) issues shares of Common Stock to a director or
officer of the Company or to a person that as a result of such issuance becomes a holder of at least five percent (5%) of the Common Stock of the Company, the Company will cause such purchaser of such shares of Preferred Stock or Common Stock,
as the case may be, to become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and such purchaser shall be deemed an “Investor” hereunder and Exhibit A shall be accordingly
updated. 
  

 8 

 3.10 Counterparts. This Agreement may be executed in one or more counterparts, each
of which will be deemed an original but all of which together shall constitute one and the same agreement. 
 3.11
Waiver. No waivers of any breach of this Agreement extended by any party hereto to any other party shall be construed as a waiver of any rights or remedies of any other party hereto or with respect to any subsequent breach. 
 3.12 Attorney’s Fees. In the event that any suit or action is instituted to enforce any provision in this Agreement, the
prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable
fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
 3.13 Notices. Any notices required in connection with this Agreement shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile
if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one
(1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written notification of receipt. All notices shall be addressed to the holder appearing on the books of the Company or at such address as
such party may designate by ten (10) days advance written notice to the other parties hereto. 
 3.14 Entire
Agreement. This Agreement and Exhibit A hereto, along with the Purchase Agreement and each of the Exhibits thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and
no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein and therein. 
 3.15 Grant of Proxy. Upon the failure of any party to vote their Investor Shares in accordance with the terms of this Agreement, such
party hereby grants to a stockholder designated by the Board a proxy coupled with an interest in all Investor Shares owned by such party, which proxy shall be irrevocable until this Agreement terminates pursuant to its terms or this
Section 3.15 is amended to remove such grant of proxy in accordance with Section 3.5 hereof, to vote all such Investor Shares in the manner provided in Section 1 hereof. 
 (Signature Page Follows) 
  

 9 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
 CODEXIS, INC. 
  

			
	By:	 	 /s/ Alan Shaw

	Name:	 	Alan Shaw
	Title:	 	President

 SIGNATURE PAGE TO FIFTH
AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	MAXYGEN, INC.
		
	By:	 	 /s/ Russell J. Howard

	Name:	 	Russell J. Howard
	Title:	 	CEO

 SIGNATURE PAGE TO FIFTH AMENDED AND
RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	CMEA VENTURES LIFE SCIENCES 2000, L.P.
		
	By:	 	 /s/ Karl Handelsman

	Name:	 	Karl Handelsman
	Title:	 	General Partner
	
	 CMEA VENTURES LIFE SCIENCES 2000,
     CIVIL LAW PARTNERSHIP

		
	By:	 	 /s/ Karl Handelsman

	Name:	 	Karl Handelsman
	Title:	 	General Partner

 SIGNATURE PAGE TO FIFTH
AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
 FIRSTMARK III, L.P. 
 (formerly, Pequot
Private Equity Fund III, L.P.) 
  

			
	By:	 	 /s/ Brian Kempner

	Name:	 	
	Title:	 	

 FIRSTMARK III Offshore Partners, L.P. 
 (formerly, Pequot Offshore Private Equity Partners III, L.P.) 
  

			
	
	
	By:	 	 /s/ Brian Kempner

	Name:	 	
	Title:	 	

 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	 PFIZER IRELAND PHARMACEUTICALS
 (formerly, Pfizer Overseas Pharmaceuticals)

		
	By:	 	 /s/ Paul Duffy

	Name:	 	Paul Duffy
	Title:	 	Director

 SIGNATURE PAGE TO FIFTH
AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
 BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD 
  

			
	By:	 	 /s/ Chu Swee Yeok

	Name:	 	Chu Swee Yeok
	Title:	 	Director

 SIGNATURE PAGE TO FIFTH
AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	ROBERT W. CRANMER-BROWN
		
	By:	 	 /s/ Robert W. Cranmer-Brown

	Name:	 	Robert W. Cranmer-Brown

 SIGNATURE PAGE
TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	THE CONUS FUND, L.P.
		
	By:	 	 /s/ Andrew D. Zacks

	Name:	 	Andrew D. Zacks
	Title:	 	 Managing Member, General Partner
 Conus Capital, LLC

 THE CONUS FUND OFFSHORE MASTER FUND LTD. 
  

			
	By:	 	 /s/ Andrew D. Zacks

	Name:	 	Andrew D. Zacks
	Title:	 	Managing Director, Investment Manager Conus Partners, Inc
	
	THE CONUS FUND (QP) L.P.
		
	By:	 	 /s/ Andrew D. Zacks

	Name:	 	Andrew D. Zacks
	Title:	 	 Managing Member, General Partner
 Conus Capital, LLC

 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
 EQUILON ENTERPRISES LLC DBA SHELL OIL PRODUCTS US 
  

			
	By:	 	 /s/ Richard M. Oblath

	Name:	 	Richard M. Oblath
	Title:	 	Attorney in Fact

 SIGNATURE PAGE TO
FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	MALAYSIAN LIFE SCIENCES CAPITAL FUND, LTD.
		
	Malaysian Life Sciences Capital Fund Management	  	
	Company Ltd, its Manager	  	

  

			
	By:	 	 /s/ Dr. Roger Earl Wyse

	Name:	 	Dr. Roger Earl Wyse
	Title:	 	Co-Chairman

 SIGNATURE PAGE TO FIFTH
AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	COOK INLET REGION, INC.
		
	By:	 	 /s/ Stig A. Colberg

	Name:	 	Stig A. Colberg
	Title:	 	Vice President, Business Development

 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
 MALAYSIAN TECHNOLOGY DEVELOPMENT CORPORATION SDN. BHD. 
  

			
	By:	 	 /s/ Norhalim Yunus

	Name:	 	
	Title:	 	

 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above written. 
  

			
	GREENER CAPITAL PARTNERS, L.P.
		
	By:	 	Greener Capital Equity, L.L.C.
		 	Its general partner
		
	By:	 	 /s/ Charles H. Finnie

	Name:	 	Charles H. Finnie
	Title:	 	Managing Partner

 SIGNATURE PAGE TO
FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 EXHIBIT A 
 LIST OF INVESTORS 
 Maxygen, Inc. 
 CMEA Ventures Life Sciences 2000, L.P. 
 CMEA
Ventures Life Sciences 2000, Civil Law Partnership 
 CTTV Investments LLC 
 FirstMark III, L.P. 
 FirstMark III Offshore Partners, L.P. 
 Pfizer Overseas Pharmaceuticals 
 Biomedical
Sciences Investment Fund Pte Ltd 
 Robert W. Cranmer-Brown 
 The Conus Fund, L.P. 
 The Conus Fund Offshore Master Fund Ltd. 
 The Conus Fund (QP) L.P. 
 Equilon Enterprises LLC
dba Shell Oil Products US 
 GPSF Securities Inc. 
 Malaysian Life Sciences Capital Fund, Ltd. 
 AFAC Equity, L.P. 
 Cook Inlet Region, Inc. 
 Malaysian Technology
Development Corporation Sdn. Bhd. 
 Greener Capital Partners, L.P.Amendment to Fifth Amended and Restated Voting Agreement

 Exhibit 4.10 
 CODEXIS, INC. 
 AMENDMENT 
 TO 
 FIFTH AMENDED AND RESTATED VOTING AGREEMENT 
 This Amendment to Fifth Amended and Restated Voting
Agreement (the “Amendment”) is made and entered into as of February 25, 2010, by and among Codexis, Inc., a Delaware corporation (the “Company”) and the other parties to that certain Fifth Amended and Restated
Voting Agreement (the “Voting Agreement”), dated as of March 4, 2009, by and among the Company and the persons and entities listed on Exhibit A attached hereto (the “Investors”). 
 RECITALS 
 WHEREAS, Sections 1.3(a) and (b) of the Voting Agreement provide that so long as Equilon Enterprises LLC dba Shell Oil Products US and its affiliates (“Shell”) meet certain requirements with respect to ownership of the
Company’s capital stock and that certain Amended and Restated Collaborative Research Agreement, entered into as of November 1, 2007 and effective as of November 1, 2006, as amended, between Shell and the Company, has not expired or
been terminated (other than a termination by Shell arising out of or resulting from a breach of such agreement by the Company), Shell shall have the right to designate two (2) nominees (the “Shell Representatives”) to the
Company’s Board of Directors (the “Board”); 
 WHEREAS, pursuant to Section 2.1 of the Voting
Agreement, other than Sections 1.3(a), 1.3(b), 2.2 and 3 (except for Sections 3.1, 3.2 and 3.9) thereof relating to the Shell Representatives, the provisions of the Voting Agreement terminate upon the earliest of certain events, including
immediately prior to the closing of a firmly underwritten public offering of the common stock of the Company (“Common Stock”) pursuant to a registration statement filed with the Securities and Exchange Commission, and declared
effective under the Securities Act of 1933, as amended, which results in the Series A Preferred Stock of the Company (“Series A Preferred Stock”), Series B Preferred Stock of the Company (“Series B Preferred
Stock”), Series C Preferred Stock of the Company (“Series C Preferred Stock”), Series D Preferred Stock of the Company (“Series D Preferred Stock”), Series E Preferred Stock of the Company (“Series
E Preferred Stock”) and Series F Preferred Stock of the Company (“Series F Preferred Stock”, and together with the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D
Preferred Stock and the Series E Preferred Stock, the “Preferred Stock”) of the Company being converted into Common Stock; 
 WHEREAS, the Company and the Investors may amend the Voting Agreement pursuant to Section 3.5 thereof with the written consent of (i) the Company and (ii) the holders of at least a majority
of the Preferred Stock, voting together as a single class on an as-converted basis and including any Common Stock issued upon conversion; provided, however, that notwithstanding the foregoing, the consent of any Investor having the right to
designate or remove a director pursuant to Section 1.3 of the Voting Agreement and/or a committee appointment right pursuant to Section 1.4, as applicable, shall be required for any amendment, supplement, modification or waiver of such
rights (provided at the time of such amendment, supplement, modification or waiver, such Investor owns at least fifty percent (50%) of the total number of shares of Common Stock issued or issuable upon conversion of the shares of the relevant
series of Preferred Stock purchased by such Investor, which shares are held by such Investor as of the date of the Voting Agreement (as adjusted for conversions, stock splits, dividends and the like)); 

 WHEREAS, the Company, the Investors and Shell desire to amend the Voting Agreement to
decrease the number of Shell Representatives to the Board to one (1), effective as of the date of this Amendment. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained in this
Amendment and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree that the Voting Agreement shall be amended as follows: 
 1. Amendment to Section 1.3. Section 1.3 of the Voting Agreement shall be amended and restated in its entirety as follows:

 “1.3 Election of Directors. On all matters relating to the election of directors of the Company, the Investors
agree to vote all Investor Shares held by them (or the holders thereof shall consent pursuant to an action by written consent of the holders of capital stock of the Company) so as to elect (whether through a class vote, cumulative voting or
otherwise) members of the Board, as follows: 
 (a) one (1) nominee of the Series E Preferred Stock and Series F Preferred
Stock designated by Equilon Enterprises LLC dba Shell Oil Products US (the “Shell Representative”), so long as (i) Equilon Enterprises LLC dba Shell Oil Products US and its affiliates (“Shell”) hold on the date
of such designation not less than (A) fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series E Preferred Stock originally purchased by Shell (as adjusted for conversions, stock
splits, dividends and the like) or (B) fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series F Preferred Stock originally purchased by Shell (as adjusted for conversions, stock
splits, dividends and the like), (ii) Shell holds on the date of such designation not less than five percent (5%) of the Fully Diluted Capitalization (as defined below), and (iii) that certain Amended and Restated Collaborative
Research Agreement, entered into as of November 1, 2007 and effective as of November 1, 2006, as amended, between Shell and the Company, has not expired or been terminated (other than a termination by Shell arising out of or resulting from
a breach of such agreement by the Company) prior to or on the date of such designation, which designee shall initially be Chris Streng; provided, however, that, after the IPO, Shell’s designation of a nominee shall be subject to the reasonable
approval of a majority of the members of the Board or the applicable committee of the Board other than the Shell Representative; 
 (b) [INTENTIONALLY OMITTED] 
 (c) one (1) nominee of the Series D Preferred Stock designated by Biomedical
Sciences Investment Fund Pte Ltd (the “Bio*One Representative”), so long as Biomedical Sciences Investment Fund Pte Ltd and its affiliates (“Bio*One”) hold not less than fifty percent (50%) of the total number
of shares of Common Stock issuable or issued upon conversion of the Series D Preferred Stock originally purchased by Bio*One (as adjusted for conversions, stock splits, dividends and the like) on the date of such designation, which designee shall
initially be Mun Yew Wong, M.D.; 
  

 2 

 (d) two (2) nominees of the Series B Preferred Stock designated as follows: 

(i) one (1) nominee designated by CMEA Ventures Life Sciences 2000, L.P. (the “CMEA Representative”), so long as
CMEA Ventures Life Sciences 2000, L.P. and its affiliates (“CMEA”) hold not less than fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series B Preferred Stock
originally purchased by CMEA (as adjusted for conversions, stock splits, dividends and the like) on the date of such designation, which designee shall initially be Thomas Baruch; and 
 (ii) one (1) nominee designated by FirstMark III, L.P. and its affiliates (the “FirstMark Representative”), so long
as FirstMark III, L.P. and its affiliates (“FirstMark”) hold not less than fifty percent (50%) of the total number of shares of Common Stock issuable or issued upon conversion of the Series B Preferred Stock originally
purchased by FirstMark (as adjusted for conversions, stock splits, dividends and the like) on the date of such designation, which designee shall initially be Alexander A. Karsner; 
 (e) One (1) nominee of the Series A Preferred Stock designated by Maxygen, Inc., a Delaware corporation (“Maxygen”),
so long as Maxygen and its affiliates hold not less than fifty percent (50%) of the total number shares of Common Stock issuable or issued upon conversion of the Series A Preferred Stock originally purchased by Maxygen (as adjusted for
conversions, stock splits, dividends and the like) on the date of such designation, which designee shall initially be James R. Sulat; 
 (f) the person serving as Chief Executive Officer of the Company, or if there is no duly elected Chief Executive Officer, a nominee chosen from Company management by the parties hereto holding a majority of the outstanding Common Stock and
Preferred Stock, voting together as a single class on an as converted to Common Stock basis; and 
 (g) three
(3) independent nominees, designated with the consent of the parties hereto holding a majority of the outstanding Common Stock and Preferred Stock, voting together as a single class on an as-converted to Common Stock basis, which designees
shall initially be Bernard J. Kelley, Bruce Pasternack, and Dennis P. Wolf. 
 Any vote taken to remove any director elected
pursuant to this Section 1.3, or to fill any vacancy created by the resignation, removal or death of a director elected pursuant to this Section 1.3, shall also be subject to the provisions of this Section 1.3 (i.e., removal shall be
upon the written recommendation of the party/group that nominated such director and any vacancy shall be filled upon the written recommendation of the party/group that nominated the director previously filling the position); provided, however, that,
after the IPO, Shell’s designation of a nominee shall be subject to the reasonable approval of a majority of the members of the Board or the applicable committee of the Board other than the Shell Representative. 
  

 3 

 If the Company adopts a classified board structure, subject to the fiduciary duties of the
Board under applicable law, Shell shall have the right to determine the class in which the Shell Representative shall serve at the time of such initial designation by the Board. 
 “Fully Diluted Capitalization,” at any particular time, means the sum of: (a) the total number of shares of Common
Stock that are issued and outstanding at such time; (b) the total number of shares of Common Stock that are issuable upon the conversion in full of all shares of Preferred Stock issued and outstanding at such time; (c) the total number of
shares of Common Stock that are issuable upon the conversion or exercise in full of all convertible securities, options, warrants or other rights to acquire Common Stock or Preferred Stock that are outstanding at such time (whether vested or
unvested); and (d) the total number of shares of Common Stock that are available for grant or issuance (but not outstanding) under the Company’s option and other benefit plans.” 
 2. Amendment to Section 1.4. Section 1.4 of the Voting Agreement shall be amended and restated in its entirety as follows:

 “1.4 Board Committee Representation/Chairman. Each of the Shell Representative, the CMEA Representative, the
FirstMark Representative and the Bio*One Representative shall have the right, but not the obligation, to be a member of any committee of the Board.” 
 3. Amendment to Section 2.1. Section 2.1 of the Voting Agreement shall be amended and restated in its entirety as follows: 
 “2.1 General Termination. Subject to Section 2.2 with respect to Shell only, this Agreement shall continue in full force
and effect from the date hereof through the earliest of the following times, at which time the provisions of this Agreement, other than Sections 1.3(a), 2.2 and 3 (except for Sections 3.1, 3.2 and 3.9) hereof (collectively, the “Shell
Provisions”), shall terminate in their entirety: 
  

	 	(a)	immediately prior to the closing of a firmly underwritten public offering of the Common Stock pursuant to a registration statement filed with the Securities and
Exchange Commission, and declared effective under the Securities Act of 1933, as amended, which results in the Preferred Stock being converted into Common Stock (the “IPO”); 

  

	 	(b)	ten (10) years from the date of this Agreement; 

  

	 	(c)	immediately prior to the closing of a sale, lease, or other disposition of all or substantially all of the Company’s assets or the Company’s merger into or
consolidation with any other corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such
transaction, securities representing less than fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction; provided, however, that this Section 2.1(c) shall not apply to a merger
effected exclusively for the purpose of changing the domicile of the Company (a “Change in Control”); or 

  

 4 

	 	(d)	the date as of which the parties hereto terminate this Agreement by written consent of: 

  

	 	(i)	Maxygen (provided at the time of termination Maxygen and its affiliates own at least fifty percent (50%) of the total number shares of Series A Preferred Stock
outstanding as of the date hereof (as adjusted for conversions, stock splits, dividends and the like)), 

  

	 	(ii)	CMEA (provided at the time of termination CMEA owns at least fifty percent (50%) of the total number of shares of Series B Preferred Stock held as of the date
hereof (as adjusted for conversions, stock splits, dividends and the like)), 

  

	 	(iii)	FirstMark (provided at the time of termination FirstMark owns at least fifty percent (50%) of the total number of shares of Series B Preferred Stock held as of the
date hereof (as adjusted for conversions, stock splits, dividends and the like)), 

  

	 	(iv)	Bio*One (provided at the time of termination Bio*One owns at least fifty percent (50%) of the total number of shares of Series D Preferred Stock held as of the
date hereof (as adjusted for conversions, stock splits, dividends and the like)), 

  

	 	(v)	Shell (provided that, on the date of such written consent, Shell retains the right to elect the Shell Representative pursuant to Sections 1.3(a)) and

  

	 	(vi)	a majority in interest of, collectively, the Investors.” 

 4. Amendment to Section 2.2. Section 2.2 of the Voting Agreement shall be amended and restated in its entirety as follows: 
 “2.2 Shell Termination. For the benefit of Shell only, the Shell Provisions of this Agreement shall continue in full force and
effect from the date hereof through the earliest of the following dates, on which date the Shell Provisions (except for the last sentence of this Section 2.2, which shall terminate after the resignation of the Shell Representative) shall terminate
in their entirety: 
  

	 	(a)	ten (10) years from the date of this Agreement; 

  

	 	(b)	immediately prior to the closing of a Change in Control; 

  

	 	(c)	the date as of which the parties hereto terminate this Agreement with the written consent of Shell (provided at the time of termination Shell owns at least fifty
percent (50%) of the total number of shares of Common Stock issued or issuable upon conversion of the Series E Preferred Stock and the Series F Preferred Stock (voting together as a single class and not as a separate series and on an
as-if-converted basis) originally purchased by Shell (as adjusted for conversions, stock splits, dividends and the like)); 

  

 5 

	 	(d)	the date as of which Shell holds less than five percent (5%) of the Fully Diluted Capitalization; or 

  

	 	(e)	the date as of which that certain Amended and Restated Collaborative Research Agreement, entered into as of November 1, 2007 and effective as of November 1,
2006, as amended, has expired or been terminated other than a termination by Shell arising out of or resulting from a breach of such agreement by the Company (each of such times in Sections 2.2(a) through 2.2(e) hereof being a “Shell
Termination Trigger”). 

 Upon a Shell Termination Trigger, Shell shall cause the Shell Representative to
resign from the Board and any committees of the Board on which such Shell Representative sits, upon the request of a majority of the members of the Board or the applicable committees of the Board other than the Shell Representative.”

 2. Entire Agreement. This Amendment, together with the Voting Agreement (to the extent not amended hereby) and all
exhibits thereto (to the extent not amended hereby), represent the entire agreements of the parties and shall supersede any and all previous contracts, arrangements or understandings between the parties with respect to the subject matter herein.

 3. Governing Law. This Amendment, and the rights of the parties hereto, shall be governed by and construed in
accordance with the laws of the State of Delaware as such laws apply to agreements among Delaware residents made and to be performed entirely within the State of Delaware. 
 4. Underlying Obligations. Except as otherwise expressly stated in this Amendment, all of the terms and provisions of the Voting
Agreement shall remain in full force and effect, without amendment or modification. The Company and the Investors agree that this Amendment shall not be construed as an agreement to extinguish the Company’s original obligations under the Voting
Agreement and shall not constitute a novation as to the obligations of the Company under the Voting Agreement. 
 5.
Counterparts. This Amendment may be executed in one or more counterparts, each of which will be deemed an original but all of which together shall constitute one and the same agreement. 
 (Signature Page Follows) 
  

 6 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	CODEXIS, INC.
		
	By:	 	 /s/ Alan Shaw

	Name:	 	Alan Shaw
	Title:	 	President

 SIGNATURE PAGE TO AMENDMENT
TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	MAXYGEN, INC.
		
	By:	 	 /s/ James R. Sulat

	Name:	 	James R. Sulat
	Title:	 	CEO & CFO

 SIGNATURE PAGE TO
AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	CMEA VENTURES LIFE SCIENCES 2000, L.P.
		
	By:	 	 /s/ Thomas R. Baruch

	Name:	 	Thomas R. Baruch
	Title:	 	Managing Director
	
	 CMEA VENTURES LIFE SCIENCES 2000, CIVIL LAW PARTNERSHIP

		
	By:	 	 /s/ Thomas R. Baruch

	Name:	 	Thomas R. Baruch
	Title:	 	Managing Director

 SIGNATURE PAGE TO
AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	FIRSTMARK III, L.P.
	(formerly, Pequot Private Equity Fund III, L.P.)
		
	By:	 	FirstMark Capital, LLC, Investment Manager
		
	By:	 	 /s/ Brian Kempner

	Name:	 	Brian Kempner
	Title:	 	Chief Operating Officer
	
	FIRSTMARK III Offshore Partners, L.P.
	(formerly, Pequot Offshore Private Equity Partners III, L.P.)
		
	By:	 	FirstMark Capital, LLC, Investment Manager
		
	By:	 	 /s/ Brian Kempner

	Name:	 	Brian Kempner
	Title:	 	Chief Operating Officer

 SIGNATURE PAGE TO
AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	CTTV INVESTMENTS LLC
		
	By:	 	 /s/ Don C. Riley

	Name:	 	Don C. Riley
	Title:	 	Venture Executive

 SIGNATURE PAGE TO
AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	PFIZER IRELAND PHARMACEUTICALS
	(formerly, Pfizer Overseas Pharmaceuticals)
		
	By:	 	 /s/ Paul Duffy

	Name:	 	Paul Duffy
	Title:	 	Director

 SIGNATURE PAGE TO AMENDMENT TO
FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD
		
	By:	 	 /s/ Chu Swee Yeok

	Name:	 	Chu Swee Yeok
	Title:	 	Director

 SIGNATURE PAGE TO AMENDMENT TO
FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	THE CONUS FUND, L.P.
		
	By:	 	 /s/ Andrew D. Zacks

	Name:	 	Andrew D. Zacks
	Title:	 	 Manager Member, General Partner
 Conus Capital, LLC

	
	THE CONUS FUND OFFSHORE MASTER FUND LTD.
		
	By:	 	 /s/ Andrew D. Zacks

	Name:	 	Andrew D. Zacks
	Title:	 	 Managing Director, Investment Manager
 Conus Partners, Inc

	
	THE CONUS FUND (QP) L.P.
		
	By:	 	 /s/ Andrew D. Zacks

	Name:	 	Andrew D. Zacks
	Title:	 	 Managing Member, General Partner
 Conus Capital, LLC

 SIGNATURE PAGE TO AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	EQUILON ENTERPRISES LLC DBA SHELL OIL PRODUCTS US

			
		
	By:	 	 /s/ Tom N. Smith

	Name:	 	Tom N. Smith
	Title:	 	President

 SIGNATURE PAGE TO AMENDMENT
TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
 MALAYSIAN LIFE SCIENCES CAPITAL FUND, LTD. 
  

			
	By:	 	  

		 	Malaysian Life Sciences Capital Fund Management
		 	Company Ltd, its Manager
		
	By:	 	 /s/ Dr. Roger Earl Wyse

	Name:	 	Dr. Roger Earl Wyse
	Title:	 	Co-Chairman

 SIGNATURE PAGE TO AMENDMENT
TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT as of the date first above
written. 
  

			
	COOK INLET REGION, INC.
		
	By:	 	 /s/ Stig A. Colberg

	Name:	 	Stig A. Colberg
	Title:	 	Vice President, Business Development

 SIGNATURE PAGE TO AMENDMENT TO FIFTH AMENDED AND RESTATED VOTING AGREEMENT 

 EXHIBIT A 
 LIST OF INVESTORS 
 Maxygen, Inc. 
 CMEA Ventures Life Sciences 2000, L.P. 
 CMEA
Ventures Life Sciences 2000, Civil Law Partnership 
 CTTV Investments LLC 
 FirstMark III, L.P. 
 FirstMark III Offshore Partners, L.P. 
 Pfizer Overseas Pharmaceuticals 
 Biomedical
Sciences Investment Fund Pte Ltd 
 Robert W. Cranmer-Brown 
 The Conus Fund, L.P. 
 The Conus Fund Offshore Master Fund Ltd. 
 The Conus Fund (QP) L.P. 
 Equilon Enterprises LLC
dba Shell Oil Products US 
 GPSF Securities Inc. 
 Malaysian Life Sciences Capital Fund, Ltd. 
 AFAC Equity, L.P. 
 Cook Inlet Region, Inc. 
 Malaysian Technology
Development Corporation Sdn. Bhd. 
 Greener Capital Partners, L.P.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]